Ignite Creation Date:
2024-05-06 @ 7:09 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05918042
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2023-06-15
Brief Title:
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD Status in Russian Federation
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Multicentre Non-interventional Observational Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD Ovarian Cancer Patients in Russian Federation
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OVARD
Brief Summary:
Study population will consist of HRD BRCAm - positive genomic instability score according to used test system OC with available medical history It is estimated that approximately 400 patients will be enrolled in approximately 25 sites Demographic and clinical characteristics treatment approaches and outcomes in HRD patients with high-grade epithelial ovarian primary peritoneal andor fallopian tube cancer will be collected at baseline and on prospective visits
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None